Filing Flows › Thermo Fisher Scientific (TMO) › Laboratory Products and Biopharma Services revenue
Thermo Fisher Scientific (TMO) Laboratory Products and Biopharma Services revenue by quarter
Thermo Fisher Scientific's Laboratory Products and Biopharma Services revenue was $6.8B in Q3 2026 (third quarter 2026), +3% from Q2 2026. Over the last 5 quarters it ranged from $5.9B (Q3 2025) to $6.8B (Q3 2026).
| Quarter | Laboratory Products and Biopharma Services revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $6.8B | +3% | +15% |
| Q2 2026 | $6.7B | +11% | — |
| Q1 2026 | $6.0B | -5% | — |
| Q4 2025 | $6.3B | +7% | — |
| Q3 2025 | $5.9B | — | — |
Q3 2026 at a glance
Thermo Fisher Scientific, Q3 2026: revenue $12.1B (+9% year over year), operating margin 18.6%, net earnings $1.7B, operating cash flow $2.5B. The chart follows the revenue to costs, profit and cash.
Questions
What is Thermo Fisher Scientific's Laboratory Products and Biopharma Services revenue?
Thermo Fisher Scientific's Laboratory Products and Biopharma Services revenue was $6.8B in Q3 2026 (third quarter 2026), +3% from Q2 2026.
How has Thermo Fisher Scientific's Laboratory Products and Biopharma Services revenue changed?
Over the last 5 quarters it ranged from $5.9B (Q3 2025) to $6.8B (Q3 2026).
Q3 2026 results → · How Thermo Fisher Scientific makes money →